Latest Human anti-mouse antibody Stories
BURLINGAME, Calif., Sept. 20 /PRNewswire/ -- Epitomics, Inc. today announced that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has chosen the company to distribute a panel of LRRK2 monoclonal antibodies that were developed under an agreement between the two parties.
By 2012, sales of monoclonal antibodies will represent nearly 50% of oncology drug sales, according to a new study by Cutting Edge Information. Successful brands such as Rituxan, Herceptin and Erbitux are all expected to grow by anywhere from 23% to 80% by 2013.
- A trick or prank.